ClinicalTrials.gg
SuspendedNCT05445609Updated Oct 13, 2026

Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

A Phase 2 interventional study of VLP-encapsulated TLR9 Agonist CMP-001, and Nivolumab in Metastatic Prostate Adenocarcinoma and Stage IV Prostate Cancer AJCC v8, sponsored by Emory University. Suspended at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Emory University · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Why this study was suspended
Per sponsor memo screening and enrollment of new patients for all ongoing Regeneron sponsored studies with vidutolimod are being paused until further notice
Updated Oct 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Prostatic Neoplasms by Emory University — 7 open to participants now, 9 under way, 1 of them phase 3. Prostatic Neoplasms · Emory University.

Planned enrollment
17th of 25
10 · median 30
Started
2023
with 2 others
Phase 2
11 of 25
2 open now
Registered
18th of 25
by date

Among the 25 studies in Prostatic Neoplasms by Emory University, this one is the 17th largest by planned enrollment, is one of 3 that started in 2023, is one of 11 in phase 2, and was the 18th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

7 of the 25 studies in Prostatic Neoplasms by Emory University are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Prostatic Neoplasms by Emory University, or all of them as a file.
02

Study summary

This phase II trial tests whether vidutolimod with nivolumab works to destroy tumor cells in patients with castration resistant prostate cancer that has spread to other places in the body (metastatic). Nivolumab is an antibody working by attaching to and blocking a molecule called PD 1. PD 1 is a protein that is present on different types of cells in the immune system and controls parts of the immune system by shutting it down. Antibodies (proteins in the immune system which act to stop infection harming the body) that block PD 1 can potentially prevent PD 1 from shutting down the immune system, thus allowing immune cells to recognize and destroy cancer cells. Vidutolimod (CMP-001) is a Toll-like receptor 9 (TLR9) agonist, with the ability to generate tumor-targeted T cells capable of killing a tumor both locally and systemically in combination with checkpoint inhibitors (nivolumab, in this case), thus potentially improving outcomes for people whose tumors are progressing. Giving nivolumab and vidutolimod may kill more cancer cells in patients with metastatic prostate cancer.

Read the detailed description

Primary Objective:

I. To evaluate the safety and tolerability of vidutolimod (CMP-001) in combination with nivolumab in patients with metastatic castration resistant prostate cancer.

Secondary Objectives:

I. To evaluate prostate-specific antigen (PSA) response rate. II.To evaluate PSA undetectable rate. III. To evaluate time to PSA progression according to PCWG3. IV. To evaluate the confirmed objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1.

V. To evaluate the 1-year radiographic progression free survival (rPFS) according to PCWG3.

VI. To determine the 1-year overall survival (OS). VII. To evaluate the confirmed ORR by immune-related RECIST (irRECIST).

Exploratory Objective:

I. To evaluate the effect of treatment on the following changes, and others:

Ia. Numbers of CD8 T-cells in tumors; Ib. Dendritic cell activation status (CD80, CD86, CD40) in tissue biopsy; Ic. Tumor specific T-cells in the blood (human leukocyte antigen [HLA]-DR+/CD38+ with T-cell receptor [TCR] sequencing).

OUTLINE:

Patients receive vidutolimod subcutaneously (SC) on days 1 and 7 of cycle 1, intratumorally (IT) on day 14 of cycle 1 and days 1 and 14 of cycle 2, and then SC on day 1 of subsequent cycles. Patients also receive nivolumab intravenously (IV) over 30 minutes on days 1 and 14 of cycle 2 and on day 1 of subsequent cycles. Cycles of nivolumab repeat every 4 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity. Cycles of vidutolimod repeat every 4 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity.

After completion of the study treatment, patients are followed up for 30 days and then every 12 weeks thereafter.

03

Conditions studied

  • Metastatic Prostate Adenocarcinoma
  • Stage IV Prostate Cancer AJCC v8

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male >= 18 years of age
  • confirmed adenocarcinoma of the prostate with disease
  • Subjects who are to a novel antiandrogen therapy (abiraterone, darolutamide, enzalutamide and/or apalutamide) and have failed at least 1 taxane based chemotherapy regimen (or who are deemed medically unsuitable to be treated with a taxane regimen or have actively refused treatment with a taxane regimen)
  • Prior orchiectomy or serum testosterone levels \< 50 ng/dL determined within 4 weeks prior to start of study drug
  • Having per 1.1 (at least one additional lesion >= 0.5 cm amenable to repeated IT injection per investigator)
  • performance status of 0 or 1
  • >= 1,000/mm\^3 (within 4 weeks prior to the first dose of CMP-001)
  • count >= 100,000/mm\^3 (within 4 weeks prior to the first dose of CMP-001)
  • concentration >= 9 g/dL (within 4 weeks prior to the first dose of CMP-001)
  • Total =\< 1.5 times the (ULN) with the following exception: subjects with Gilbert Disease serum bilirubin >= 3 times ULN (within 4 weeks prior to the first dose of CMP-001)
  • (AST) and alanine aminotransferase (ALT) =\< 3 times the ULN or =\< 5 times the ULN for patients with active liver metastases (within 4 weeks prior to the first dose of CMP-001)
  • Serum creatinine =\< 1.5 times the ULN or calculated >= 40 mL/min (>= 0.67 mL/sec) using the Cockcroft-Gault equation (within 4 weeks prior to the first dose of CMP-001)
  • Subjects should have an (INR) or a partial thromboplastin time (PTT) =\< 1.5 x ULN unless the subject is receiving anticoagulant therapy (within 4 weeks prior to the first dose of CMP-001). Subjects on anticoagulant therapy should have a prothrombin time (PT) or PTT within therapeutic range of intended use and no history of severe hemorrhage. Patients who require therapeutic anticoagulation and cannot discontinue anticoagulation safely during the day prior, day of, and day after injection are excluded. Patients requiring anticoagulation with warfarin are excluded unless they can be transitioned to an alternative anticoagulant (e.g., low molecular weight heparin or direct oral anticoagulants) prior to enrollment. Antiplatelet agents (e.g., aspirin, clopidogrel, etc.) are not considered anticoagulants for the purposes of this study (i.e., they are allowed)
  • Willingness to provide pre- and post-treatment fresh tumor , if safe and medically feasible
  • Male subjects must be surgically sterile or must agree to use adequate method of from the time of consent until at least 120 days after the last dose of CMP-001
  • Willingness and ability of the subject to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, other study procedures, and study restrictions
  • Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, immunotherapy, or therapy) for the treatment of cancer >= 2 weeks before the start of study therapy. (No radiotherapy to CMP-001 injection site within 4 weeks)
  • Evidence of a personally signed indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation

Exclusion criteria

Exclusion Criteria:

  • Pathological finding consistent with pure small cell, neuroendocrine carcinoma of prostate or any other histology different from adenocarcinoma
  • Requires systemic pharmacologic doses of > 10 mg/day prednisone within 7 days prior to the first dose of CMP-001 on C1D1

    • Subjects who are currently receiving steroids at a prednisone-equivalent dose of =\< 10 mg/day do not need to discontinue steroids prior to enrollment
    • Replacement doses, topical, ophthalmologic and inhalational steroids are permitted
  • History of immune-related adverse event (AE) that required permanent discontinuation of anti-PD1/PDL1 antibody
  • History of (non-infectious) pneumonitis that required steroids or current pneumonitis
  • Patients with active disease
  • Known history of immunodeficiency
  • Known additional that is progressing or requires active treatment within the past 3 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, ductal carcinoma in situ, non-invasive bladder cancer and thyroid cancer (except anaplastic)
  • Untreated, symptomatic, or growing central nervous system (CNS)

    • Patients with treated and stable (defined as non-progression on a restaging contrast enhanced magnetic resonance imaging (MRI) or computed tomography (CT) at least 30 days after CNS directed therapy) CNS disease are eligible to enroll
    • Patients with treated and stable CNS disease enrolled on study must be willing to undergo restaging contrast-enhanced CT or MRI every 12 weeks
  • Prior allogenic tissue/solid organ transplant
  • Known infection with , virus or virus; testing is not required unless suspected
  • Received a within 30 days prior to the first dose of CMP-001 on D1. Seasonal flu vaccines that do not contain live virus or COVID vaccines that administered more than 1 week prior to first dose of CMP-001 on D1 the are permitted
  • Active infection requiring systemic therapy
  • Severe uncontrolled cardiac disease within 6 months prior to consent, including but not limited to uncontrolled hypertension; unstable angina; myocardial infarction or cerebrovascular accident. Implanted or continuous use of a pacemaker or defibrillator
  • Any concurrent uncontrolled illness, including mental illness or substance abuse, which in the opinion of the Investigator, would make the subject unable to cooperate or participate in the trial
  • Adverse event related to previously administered anti-cancer therapy that has not resolved to \< grade 2 prior to the first dose of CMP-001 on day 1 (D1)
  • Participation in another clinical study of an anti-cancer therapy or device within 28 days prior to the first dose of CMP-001 on D1
  • Received chemotherapy, radiation therapy, or biological anti-cancer therapy within 14 days prior to the first dose of CMP-001 on W1D1
  • Received previous CMP-001 treatment or anti-PD1/PDL1
  • Expecting to conceive or father children within the projected duration of the study, from the time of consent until at least 120 days after the last dose of CMP-001
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Treatment ((vidutolimod, nivolumab)

    Patients receive vidutolimod SC on days 1 and 7 of cycle 1, IT on day 14 of cycle 1 and days 1 and 14 of cycle 2, and then SC on day 1 of subsequent cycles. Patients also receive nivolumab IV over 30 minutes on days 1 and 14 of cycle 2 and on day 1 of subsequent cycles. Cycles of nivolumab repeat every 4 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity. Cycles of vidutolimod repeat every 4 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity.

    Drug: VLP-encapsulated TLR9 Agonist CMP-001, · Biological: Nivolumab

Interventions

  • DrugVidutolimodStudies of VidutolimodVidutolimod pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given SC or IT

    Also known as: ARB-1598, CMP-001, CYT 003, CYT-003

  • BiologicalNivolumab

    Given IV

    Also known as: 946414-94-4, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo

06

What researchers measure

Primary outcomes

  1. Safety of Treatment

    Will be summarized descriptively using frequencies and percentages of all captured toxicities by severity and relevance.

    Time frame: Up to 24 months

Secondary outcomes

  1. Serum prostate-specific antigen (PSA) response

    Defined as: PSA decline \>= 25%, according to PCWG3. Will be calculated along with 95% exact confidence intervals (CI).

    Time frame: Up to 24 weeks from treatment initiation

  2. Radiographic progression free survival (rPFS)

    Will be determined by applicable disease criteria or death, according to PCWG3, and estimated with the Kaplan-Meier method with time-specific (e.g., 6-month, 12-month) rate estimated with 95% CI.

    Time frame: At 1 year

  3. Overall survival (OS)

    Will be estimated with the Kaplan-Meier method with time-specific (e.g., 6-month, 12-month) rate estimated with 95% CI.

    Time frame: At 1 year

  4. Objective response rate (ORR)

    Will be determined by immune-related Response Evaluation Criteria in Solid Tumors (irRECIST),

    Time frame: Up to 24 months

  5. ORR

    Will be determined based on RECIST version 1.1

    Time frame: Up to 24 months

07

Study locations

1 site
  • Emory University Hospital/Winship Cancer Institute
    Atlanta, Georgia 30322, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jun 2023 (actual). Primary completion is estimated for Jun 2028, 60 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Jun 2027 → Jun 2028 and completion Jun 2028 → Jun 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2022
First posted
Jul 6, 2022
StartActual
Jun 7, 2023
Primary completionEst.
Jun 23, 2028was Jun 2027
CompletionEst.
Jun 23, 2029was Jun 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 23, 2027→Jun 23, 2028
Oct 13, 2026
Study completion
Jun 23, 2028→Jun 23, 2029
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Primary completion Jun 23, 2027→Jun 23, 2028
    Study completion Jun 23, 2028→Jun 23, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05445609
Lead sponsor
Emory University
Collaborators
National Cancer Institute (NCI), Prostate Cancer Foundation
Responsible party
Mehmet Bilen (Principal Investigator, Emory University) — Principal investigator
First posted
Jul 6, 2022
Start date
Jun 7, 2023
Primary completion
Jun 23, 2028 (estimated)
Completion
Jun 23, 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

Mehmet A Bilen, M.D.
principal investigator · Emory University Hospital/Winship Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vidutolimod

Start the discussion